Sana Biotechnology (SANA) Total Current Liabilities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Total Current Liabilities data on file, last reported at $86.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 160.18% year-over-year to $86.3 million; the trailing twelve-month figure through Mar 2026 stood at $86.3 million (up 160.18% YoY), and the FY2025 full-year result was $78.7 million, up 73.28% from the prior year.
• Total Current Liabilities improved to $86.3 million in Q1 2026, from $78.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $114.8 million in Q3 2022 to a low of $33.2 million in Q1 2025.
• A 5-year average of $72.1 million and a median of $66.6 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 166.03% in 2022 and plunged 54.78% in 2024, its largest moves.
• Tracing SANA's Total Current Liabilities over 5 years: stood at $111.5 million in 2022, then tumbled by 42.17% to $64.5 million in 2023, then fell by 29.55% to $45.4 million in 2024, then soared by 73.28% to $78.7 million in 2025, then gained by 9.58% to $86.3 million in 2026.
• Business Quant data shows SANA's Total Current Liabilities at $86.3 million in Q1 2026, $78.7 million in Q4 2025, and $35.5 million in Q3 2025.